Lilly Earnings Call Analysis: Why Zepbound Missed Earnings

Send us a text Dave brings his analysis of the Q3 Eli Lilly earnings call, and how it relates to the future of access to obesity medicine. Also there is an important clarification on the Zepbound savings card that you should not miss. #Zepbound #Mounjaro #Tirzepatide ro.co/OTP Support the show Our Book Has Been Released! Decoding GLP-1: A Guide for Friends and Family of Those On The Pen Buy Here: https://amzn.to/3Dc66d4 DNF10 Peptide Supplement I Use: https://integrativepeptides.com/AFFILITATES/OTP USE CODE "OTP10" to save 10%. A small commission is paid back to support On The Pen! MY WORK RELIES ON YOUR GENEROSITY, WAYS TO SUPPORT: Venmo: OnThePen Ca$h App: ManOnMounjaro BECOME A MEMBER: https://www.youtube.com/channel/UCDocQ-4IhVS3ihy_dW7nSKw/join 👉 My Amazon Affiliate Store: https://www.amazon.com/shop/manonthemounjaroonthepen MORE COMMUNITY! 📺 Watch Our Weekly Live Show: onthepen.tv 🆕 Discord: https://discord.gg/u4Ea8qqP 🤝 Visit Our Sponsor! GLP-1 Ro Body Plan: https://www.ro.co/otp Report The Shortage: https://www.ro.co/supply-tracker Does your insurance cover GLPs? https://www.ro.com/checker 📲 Contact Me: dave@onthepen.com Thank you for tuning in! If you found this content valuable, make sure to like, share, and subscribe to my youtube channel for more updates on GLP-1, obesity, type 2 diabetes, and... Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.